BRIEF SUMMARY ~~OF THE INVENTION~~

[0019] Recognizing the tremendous therapeutic potential of antigen binding molecules (ABMs) that have the binding specificity of the murine B-Ly1 antibody and that have been glycoengineered to enhance Fc receptor binding affinity and effector function, the present inventors developed a method for producing such ABMs. *Inter alia*, this method involves producing recombinant, chimeric antibodies or chimeric fragments thereof. The efficacy of these ABMs is further enhanced by engineering the glycosylation profile of the antibody Fc region.

[0019a] Accordingly, in one aspect, the disclosure is directed to a humanized Type II anti-CD20 antibody comprising (a) a heavy chain variable region selected from the group consisting of SEQ ID NO:32 and SEQ ID NO:40, and (b) the KV1 light chain variable region of SEQ ID NO:76.

[0019b] In another aspect, the disclosure is directed to a humanized Type-II anti-CD20 antibody comprising a heavy chain variable region having the specificity determining residues of the heavy chain variable region of the antibody of the disclosure, wherein said antibody induces higher levels of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with a sequence identical to rituximab.

[0019c] In another aspect, the disclosure is directed to a humanized Type-II anti-CD20 antibody comprising a heavy chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO: 31 or SEQ ID NO: 39 and a light chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO: 75, wherein said antibody induces higher levels of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with a sequence identical to rituximab.

[0019d] In another aspect, the disclosure is directed to an expression vector comprising a polynucleotide encoding a heavy chain variable region of the disclosure and a polynucleotide encoding a light chain variable region of the disclosure.

[0019e] In another aspect, the disclosure is directed to an isolated host cell comprising the expression vector of the disclosure or a polynucleotide encoding a heavy chain variable region of the disclosure and a polynucleotide encoding a light chain variable region of the disclosure.

[0019f] In another aspect, the disclosure is directed to a method for the production of a humanized Type-II anti-CD20 antibody of the disclosure comprising culturing the host cell of the disclosure under conditions that allow for the production of said antibody and recovering said antibody from said culture.

[0019g] In another aspect, the disclosure is directed to a humanized Type II anti-CD20 antibody, wherein the antibody is produced by the host cell of the disclosure.

[0019h] In another aspect, the disclosure is directed to a pharmaceutical composition comprising the antibody of the disclosure, or produced by the method of the disclosure, and a pharmaceutically acceptable carrier.

[0019i] In another aspect, the disclosure is directed to an antibody of the disclosure, or produced by the method of the disclosure, for use in therapy.

[0019j] In another aspect, the disclosure is directed to a use of antibody of the disclosure, or produced by the method of the disclosure, in the manufacture of a medicament for treating a B-cell disorder.

[0019k] In another aspect, the disclosure is directed to a use of the antibody of the disclosure, or produced by the method of the disclosure, in the manufacture of a medicament to treat a disorder treatable by B-cell depletion.

[0019l] In another aspect, the disclosure is directed to an of the disclosure, or produced by the method of the disclosure, for use in therapy.

[0020] Accordingly, in one ~~aspect~~example, the ~~invention~~ disclosure is directed to an isolated polynucleotide comprising: (a) a sequence selected from a group consisting of: SEQ ID NO.:5, SEQ ID NO.: 6 and SEQ ID NO.:7. (CDRs V_{H-1}); (b) a sequence selected from a group consisting of: SEQ ID NO.:21, SEQ ID NO.:22 and SEQ ID NO.:23. (CDRs V_{H-2}); and SEQ ID NO:24. In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising SEQ ID NO.:8, SEQ ID NO.: 9 and SEQ ID NO.:10. (CDRs V_L). In one ~~embodiment~~example, any of these polynucleotides encodes a fusion polypeptide.

[0021] In a further ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising SEQ ID No.:3 In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising SEQ ID No.:4. In a further ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71. In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising SEQ ID No.:75. In one ~~embodiment~~example, such polynucleotides encode fusion polypeptides.

[0022] The ~~invention~~disclosure is further directed to an isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:3, wherein said isolated polynucleotide encodes a fusion polypeptide. In an additional ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising a sequence having

at least 80% identity to SEQ ID NO:4, wherein said isolated polynucleotide encodes a fusion polypeptide. The ~~invention~~disclosure is further directed to an isolated polynucleotide comprising a sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71, wherein said isolated polynucleotide encodes a fusion polypeptide. In an additional ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:75, wherein said isolated polynucleotide encodes a fusion polypeptide.

[0023] The ~~invention~~disclosure is further directed to a polynucleotide comprising SEQ ID NO:11 (whole heavy chain), or to polynucleotides having 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO:11. The ~~invention~~disclosure is also directed to a polynucleotide comprising SEQ ID NO:12 (whole light chain), or to polynucleotides having 80%, 85%, 90%, 95% or 99% identity to SEQ ID NO:12.

[0024] The ~~invention~~disclosure is also directed to an isolated polynucleotide encoding a chimeric polypeptide having the sequence of SEQ ID No.:1. In one ~~embodiment~~example, the polynucleotide comprises a sequence encoding a polypeptide having the sequence of SEQ ID No.:1; and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse. The ~~invention~~disclosure is also directed to an isolated polynucleotide encoding a chimeric polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72. In one ~~embodiment~~example, the polynucleotide comprises a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID

No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72; and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

[0025] In yet another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide encoding a chimeric polypeptide having the sequence of SEQ ID No.:2. In one ~~embodiment~~example, the polynucleotide comprises a sequence encoding a polypeptide having the sequence of SEQ ID No.:2; and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse. In yet another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide encoding a chimeric polypeptide having the sequence of SEQ ID No.:76. In one ~~embodiment~~example, the polynucleotide comprises a sequence encoding a polypeptide having the sequence of SEQ ID No.:76; and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

[0026] The ~~invention~~disclosure is also directed to an isolated polynucleotide comprising a sequence encoding a polypeptide having the V_H region of the murine B-Ly1 antibody, or functional variants thereof, and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse. In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polynucleotide comprising a sequence encoding a polypeptide having the V_L region of the murine B-Ly1 antibody, or functional variants thereof, and a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

[0027] The ~~invention~~disclosure is further directed to an expression vector comprising any of the isolated polynucleotides described above, and to a host cell that comprises such an expression vector. In a further ~~aspect~~example, the ~~invention~~disclosure is directed to a host cell comprising any of the isolated polynucleotides described above.

[0028] In one ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polypeptide comprising: (a) a sequence selected from a group consisting of: SEQ ID NO.:15, SEQ ID NO.: 16 and SEQ ID NO.:17. (CDRs V_{H-1}); (b) a sequence selected from

a group consisting of: SEQ ID NO.:25, SEQ ID NO.:26 and SEQ ID NO.:27 (CDRs V_{H-2}); and SEQ ID NO:28, wherein said polypeptide is a fusion polypeptide. In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polypeptide comprising SEQ ID NO.:18, SEQ ID NO.: 19 and SEQ ID NO.:20. (CDRs V_L), wherein said polypeptide is a fusion polypeptide.

[0029] The ~~invention~~disclosure is also directed to a chimeric polypeptide comprising the sequence of SEQ ID NO.:1 or a variant thereof. The ~~invention~~disclosure is further directed to a chimeric polypeptide comprising the sequence of SEQ ID NO.:2 or a variant thereof. In one ~~embodiment~~example, any one of these polypeptides further comprises a human Fc region. The ~~invention~~disclosure is also directed to a chimeric polypeptide comprising a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, or a variant thereof. The ~~invention~~disclosure is further directed to a chimeric polypeptide comprising the sequence of SEQ ID NO.:76 or a variant thereof. In one ~~embodiment~~example, any one of these polypeptides further comprises a human Fc region.

[0030] In another ~~aspect~~example the ~~invention~~disclosure is directed to a polypeptide comprising a sequence derived from the murine B-Ly1 antibody and a sequence derived from a heterologous polypeptide and to an antigen-binding molecule comprising such a polypeptide. In one ~~embodiment~~example the antigen-binding molecule is an antibody. In a preferred ~~embodiment~~example, the antibody is chimeric. In another preferred ~~embodiment~~example, the antibody is humanized or primatized.

[0031] In an additional ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polypeptide comprising SEQ ID NO: 13 or a variant thereof. In another ~~aspect~~example, the ~~invention~~disclosure is directed to an isolated polypeptide comprising SEQ ID NO: 14.

[0032] In another ~~aspect~~example, the ~~invention~~disclosure is directed to an ABM, which is capable of competing with the murine B-Ly1 antibody for binding to CD20 and which is chimeric. In one ~~embodiment~~example, the ABM is an antibody or a fragment thereof. In a further ~~embodiment~~example, the ABM is a recombinant antibody comprising a V_H

region having an amino acid sequence selected from the group consisting of SEQ ID NO.: 1; SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72. In another ~~embodiment~~example, the ABM is a recombinant antibody comprising a V_L region having an amino acid sequence selected from the group consisting of SEQ ID NO.: 2 and SEQ ID NO:76. In a further ~~embodiment~~example the ABM is a recombinant antibody that is primatized. In yet a further ~~embodiment~~example the ABM is a recombinant antibody that is humanized. In another ~~embodiment~~example, the ABM is a recombinant antibody comprising a human Fc region. In a further ~~embodiment~~example, any of the ABMs discussed above may be conjugated to a moiety such as a toxin or a radiolabel.

[0033] The ~~invention~~disclosure is further related to an ABM of the present ~~invention~~disclosure, said ABM having modified oligosaccharides. In one ~~embodiment~~example the modified oligosaccharides have reduced fucosylation as compared to non-modified oligosaccharides. In other ~~embodiment~~examples, the modified oligosaccharides are hybrid or complex. In a further ~~embodiment~~example, the ABM has an increased proportion of nonfucosylated oligosaccharides or bisected, nonfucosylated oligosaccharides in the Fc region of said molecule. In one ~~embodiment~~example, the bisected, nonfucosylated oligosaccharides are hybrid. In a further ~~embodiment~~example, the bisected, nonfucosylated oligosaccharides are complex. In a one ~~embodiment~~example, at least 20% of the oligosacchardies in the Fc region of said polypeptide are nonfucosylated or bisected, nonfucosylated. In more preferred ~~embodiment~~examples, at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or 75% or more of the oligosaccharides are nonfucosylated or bisected, nonfucosylated.

[0034] The ~~invention~~disclosure is further related to a polynucleotide encoding any of the ABMs discussed above, and to expression vectors and cells comprising such a polynucleotide.

[0035] The ~~invention~~disclosure is further related to a method of producing an ABM, which is capable of competing with the murine B-Ly1 antibody for binding to CD20 and wherein said ABM is chimeric; said method comprising: (a) culturing a host cell

comprising a polynucleotide that encodes an ABM of the present ~~invention~~disclosure in a medium under conditions allowing the expression of said polynucleotide encoding said ABM; and (b) recovering said ABM from the resultant culture.

[0036] In another ~~aspect~~example, the ~~invention~~disclosure is related to a pharmaceutical composition comprising the ABM of the ~~invention~~disclosure. It is contemplated that the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, an adjuvant or a combination thereof.

[0037] In a further ~~aspect~~example, the ~~invention~~disclosure is related to a method of treating a disease treatable by B-cell depletion. The method comprises administering a therapeutically effective amount of the ABM of the present ~~invention~~disclosure to a human subject in need thereof. In a preferred ~~embodiment~~example, the disease is treated by administering an ABM that is a chimeric antibody, or a chimeric fragment of an antibody.

[0038] In yet another ~~aspect~~example, the ~~invention~~disclosure is related to a host cell engineered to express at least one nucleic acid encoding a polypeptide having GnTIII activity in an amount sufficient to modify the oligosaccharides in the Fc region of produced by the host cell, wherein the ABM is capable of competing with the murine B-Ly1 antibody for binding to CD20 and wherein the ABM is chimeric. In one ~~embodiment~~example, the polypeptide having GnTIII activity is a fusion polypeptide. In another ~~embodiment~~example, the ABM produced by the host cell is an antibody or an antibody fragment. In a further ~~embodiment~~example, the ABM comprises a region equivalent to the Fc region of a human IgG.

[0039] The ~~invention~~disclosure is also directed to an isolated polynucleotide comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at least the specificity-determining residues for said complementarity determining region, wherein said isolated polynucleotide encodes a fusion polypeptide. Preferably, such isolated polynucleotides encode a fusion polypeptide that is an antigen binding molecule. In one ~~embodiment~~example, the polynucleotide comprises three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity-determining residues for each of said three complementarity determining regions. In another ~~embodiment~~example, the

polynucleotide encodes the entire variable region of the light or heavy chain of a chimeric (e.g., humanized) antibody. The ~~invention~~disclosure is further directed to the polypeptides encoded by such polynucleotides.

[0040] In another ~~embodiment~~example, the ~~invention~~disclosure is directed to an antigen combining molecule comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at lest the specificity-determining residues for said complementarity determining region, and comprising a sequence derived from a heterologous polypeptide. In one ~~embodiment~~example, the antigen binding molecule comprises three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity-determining residues for each of said three complementarity determining regions. In another ~~aspect~~example, the antigen binding molecule comprises the variable region of an antibody light or heavy chain. In one particularly useful ~~embodiment~~example, the antigen binding molecule is a chimeric, e.g., humanized, antibody. The ~~invention~~disclosure is also directed to methods of making such antigen binding molecules, and the use of same in the treatment of disease, including B cell lymphomas.

[0041] The present ~~invention~~disclosure is the first known instance in which a Type II anti-CD20 antibody has been engineered to have increases effector functions such as ADCC, while still retaining potent apoptosis ability. Accordingly, the present ~~invention~~disclosure is directed to an engineered Type II anti-CD20 antibody having increased ADCC as a result of said engineering and without loss of substantial ability to induces apoptosis. In one ~~embodiment~~example, the Type II anti-CD20 antibodies have been engineered to have an altered pattern of glycosylation in the Fc region. In a particular ~~embodiment~~example, the altered glycosylation comprises an increased level of bisected complex residues in the Fc region. In another particular ~~embodiment~~example, the altered glycosylation comprises and reduced level of fucose residues in the Fc region. In another ~~embodiment~~example, the Type II anti-CD20 antibodies have undergone polypeptide engineering. he ~~invention~~disclosure is further directed to methods of making such engineered Type II antibodies and to methods of using such antibodies in the treatment of various B cell disorders, including B cell lymphomas.

[0042] The host cell of the present ~~invention~~disclosure may be selected from the group that includes, but is not limited to, a CHO cell, a BHK cell, a NSO cell, a SP2/0 cell, a YO myeloma cell, a P3X63 mouse myeloma cell, a PER cell, a PER.C6 cell or a hybridoma cell. In one ~~embodiment~~example, the host cell of the ~~invention~~disclosure further comprises a transfected polynucleotide comprising a polynucleotide encoding the V_L region of the murine B-Ly1 antibody or variants thereof and a sequence encoding a region equivalent to the Fc region of a human immunoglobulin. In another ~~embodiment~~example, the host cell of the ~~invention~~disclosure further comprises a transfected polynucleotide comprising a polynucleotide encoding the V_H region of the murine B-Ly1 antibody or variants thereof and a sequence encoding a region equivalent to the Fc region of a human immunoglobulin.

[0043] In a further ~~aspect~~example, the ~~invention~~disclosure is directed to a host cell that produces an ABM that exhibits increased Fc receptor binding affinity and/or increased effector function as a result of the modification of its oligosaccharides. In one ~~embodiment~~example, the increased binding affinity is to an Fc receptor, particularly, the FcγRIIIA receptor. The effector function contemplated herein may be selected from the group that includes, but is not limited to, increased Fc-mediated cellular cytotoxicity; increased binding to NK cells; increased binding to macrophages; increased binding to polymorphonuclear cells; increased binding to monocytes; increased direct signaling inducing apoptosis; increased dendritic cell maturation; and increased T cell priming.

[0044] In a further ~~embodiment~~example, the host cell of the present ~~invention~~disclosure comprises at least one nucleic acid encoding a polypeptide having GnTIII activity that is operably linked to a constitutive promoter element.

[0045] In another ~~aspect~~example, the ~~invention~~disclosure is directed to a method for producing an ABM in a host cell, comprising: (a) culturing a host cell engineered to express at least one polynucleotide encoding a fusion polypeptide having GnTIII activity under conditions which permit the production of said ABM and which permit the modification of the oligosaccharides present on the Fc region of said ABM; and (b) isolating said ABM; wherein said ABM is capable of competing with the murine B-Ly1 antibody for binding to CD20 and wherein said ABM is chimeric. In one ~~embodiment~~example, the polypeptide having GnTIII activity is a fusion

polypeptide, preferably comprising the catalytic domain of GnTIII and the Golgi localization domain of a heterologous Golgi resident polypeptide selected from the group consisting of the localization domain of mannosidase II, the localization domain of β(1,2)-N-acetylglucosaminyltransferase I ("GnTI"), the localization domain of mannosidase I, the localization domain of β(1,2)-N-acetylglucosaminyltransferase II ("GnTII"), and the localization domain of α1-6 core fucosyltransferase. Preferably, the Golgi localization domain is from mannosidase II or GnTI.

[0046] In a further ~~aspect~~example, the ~~invention~~disclosure is directed to a method for modifying the glycosylation profile of an anti-CD20 ABM produced by a host cell comprising introducing into the host cell at least one nucleic acid or expression vector of the ~~invention~~disclosure. In one ~~embodiment~~example, the ABM is an antibody or a fragment thereof; preferably comprising the Fc region of an IgG. Alternatively, the polypeptide is a fusion protein that includes a region equivalent to the Fc region of a human IgG.

[0047] In one ~~aspect~~example, the ~~invention~~disclosure is related to a recombinant, chimeric antibody, or a fragment thereof, capable of competing with the murine B-Ly1 antibody for binding to CD20 and having reduced fucosylation.

[0048] In another ~~aspect~~example, the present ~~invention~~disclosure is directed to a method of modifying the glycosylation of the recombinant antibody or a fragment thereof of the ~~invention~~disclosure by using a fusion polypeptide having GnTIII activity and comprising the Golgi localization domain of a heterologous Golgi resident polypeptide. In one ~~embodiment~~example, the fusion polypeptides of the ~~invention~~disclosure comprise the catalytic domain of GnTIII. In another ~~embodiment~~example, the Golgi localization domain is selected from the group consisting of: the localization domain of mannosidase II, the localization domain of GnTI, the localization domain of mannosidase I, the localization domain of GnTII and the localization domain of α1-6 core fucosyltransferase. Preferably, the Golgi localization domain is from mannosidase II or GnTI.

[0049] In one ~~embodiment~~example, the method of the ~~invention~~disclosure is directed towards producing a recombinant, chimeric antibody or a fragment thereof, with modified oligosaccharides wherein said modified oligosaccharides have reduced fucosylation as compared to non-modified oligosaccharides. According to the

present ~~invention~~disclosure, these modified oligosaccharides may be hybrid or complex. In another ~~embodiment~~example, the method of the ~~invention~~disclosure is directed towards producing a recombinant, chimeric antibody or a fragment thereof having an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said polypeptide. In one ~~embodiment~~example, the bisected, nonfucosylated oligosaccharides are hybrid. In another ~~embodiment~~example, the bisected, nonfucosylated oligosaccharides are complex. In a further ~~embodiment~~example, the method of the ~~invention~~disclosure is directed towards producing a recombinant, chimeric antibody or a fragment thereof having at least 20% of the oligosaccharides in the Fc region of said polypeptide that are bisected, nonfucosylated. In a preferred ~~embodiment~~example, at least 30% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated. In another preferred ~~embodiment~~example, wherein at least 35% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.

[0050] In a further ~~aspect~~example, the ~~invention~~disclosure is directed to a recombinant, chimeric antibody or a fragment thereof, that exhibits increased Fc receptor binding affinity and/or increased effector function as a result of the modification of its oligosaccharides. In one ~~embodiment~~example, the increased binding affinity is to an Fc activating receptor. In a further ~~embodiment~~example, the Fc receptor is Fcγ activating receptor, particularly, the FcγRIIIA receptor. The effector function contemplated herein may be selected from the group that includes, but is not limited to, increased Fc-mediated cellular cytotoxicity; increased binding to NK cells; increased binding to macrophages; increased binding to polymorphonuclear cells; increased binding to monocytes; increased direct signaling inducing apoptosis; increased dendritic cell maturation; and increased T cell priming.

[0051] In another ~~aspect~~example, the ~~invention~~disclosure is directed to a recombinant, chimeric antibody fragment, having the binding specificity of the murine B-Ly1 antibody and containing the Fc region, that is engineered to have increased effector function produced by any of the methods of the present ~~invention~~disclosure.

[0052] In another ~~aspect~~example, the present ~~invention~~disclosure is directed to a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:1 and a region equivalent to the Fc region of an immunoglobulin and engineered to have

increased effector function produced by any of the methods of the present ~~invention~~disclosure.

[0053] In another ~~aspect~~example, the present ~~invention~~disclosure is directed to a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:2 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function produced by any of the methods of the present ~~invention~~disclosure.

[0054] In one ~~aspect~~example, the present ~~invention~~disclosure is directed to a pharmaceutical composition comprising a recombinant, chimeric antibody, produced by any of the methods of the present ~~invention~~disclosure, and a pharmaceutically acceptable carrier. In another ~~aspect~~example, the present ~~invention~~disclosure is directed to a pharmaceutical composition comprising a recombinant, chimeric antibody fragment produced by any of the methods of the present ~~invention~~disclosure, and a pharmaceutically acceptable carrier. In another ~~aspect~~example, the present ~~invention~~disclosure is directed to a pharmaceutical composition comprising a fusion protein produced by any of the methods of the present ~~invention~~disclosure, and a pharmaceutically acceptable carrier.

[0055] The ~~invention~~disclosure is further directed to a method of treating a disease treatable by B-cell depletion comprising administering a therapeutically effective amount of the recombinant, chimeric, antibody or fragment thereof, produced by any of the methods of the present ~~invention~~disclosure, to a human subject in need thereof.

BRIEF DESCRIPTION OF THE FIGURES

[0056] FIG 1. Nucleotide (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:1) of the V_H region of the murine B-Ly1.

[0057] FIG 2. Nucleotide (SEQ ID NO:4) and amino acid sequence (SEQ ID NO:2) of the V_L region of the murine B-Ly1.

[0058] FIG 3. Binding of Rituximab® (O) and ch-B_Ly1 (Δ) to CD20 on Raji B-lymphoma cells.

[0059] FIG 4. B-Cell depletion by Rituximab® (O) and ch-B_Ly1 (Δ) in whole blood of the three different classes of FcγRIIIa-158V/F genotype: (A) whole blood from a F/F donor, homozygous for the lower affinity receptor; (B) whole

WHAT IS CLAIMED IS:

1. A humanized Type II anti-CD20 antibody comprising

(a) a heavy chain variable region selected from the group consisting of SEQ ID NO:32 and SEQ ID NO:40, and

(b) the KV1 light chain variable region of SEQ ID NO:76.

2. The antibody of claim 1, wherein the heavy chain variable region is SEQ ID NO: 40.

3. A humanized Type-II anti-CD20 antibody comprising a heavy chain variable region having the specificity determining residues of the heavy chain variable region of the antibody of claim 1 or claim 2, wherein said antibody induces higher levels of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with a sequence identical to rituximab.

4. A humanized Type-II anti-CD20 antibody comprising a heavy chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO: 31 or SEQ ID NO: 39 and a light chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO: 75, wherein said antibody induces higher levels of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with a sequence identical to rituximab.

~~1. An isolated polynucleotide comprising~~

~~a. a sequence selected from the group consisting of: SEQ ID NO.:5, SEQ ID NO.: 6 and SEQ ID NO:7; and~~

~~b. a sequence selected from the group consisting of:SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO:23; and~~

~~c. sequence ID NO:24.~~

~~2. An isolated polynucleotide comprising SEQ ID NO.:8, SEQ ID NO.: 9 and SEQ ID NO.:10.~~

~~3. An isolated polynucleotide according to claim 1 or claim 2, which encodes a fusion polypeptide.~~

~~4. An isolated polynucleotide comprising SEQ ID No.:3.~~

~~5. An isolated polynucleotide comprising SEQ ID No.:4.~~

~~6. An isolated polynucleotide according to claim 4 or 5, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~7. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:3, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~8. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:4, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~9. An isolated polynucleotide comprising~~

~~a. a sequence encoding a polypeptide having the sequence of SEQ ID No.:1; and~~

~~b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~10. An isolated polynucleotide comprising~~

~~a. a sequence encoding a polypeptide having the sequence of SEQ ID No.:2; and~~

~~b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~11. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No.:1.~~

~~12. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No.:2.~~

~~13. An isolated polynucleotide comprising SEQ ID NO.: 11.~~

~~14. An isolated polynucleotide comprising SEQ ID NO.: 12.~~

~~15. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.~~

~~16. An isolated polynucleotide comprising a sequence having at least 85% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.~~

~~17. An isolated polynucleotide comprising a sequence having at least 90% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.~~

~~18. An isolated polynucleotide comprising a sequence having at least 95% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.~~

~~19. An isolated polynucleotide comprising a sequence having at least 99% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.~~

~~20. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:13 (heavy chain aa).~~

~~21. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:14 (light chain aa).~~

~~22. An isolated polynucleotide comprising~~

~~a. a sequence encoding a polypeptide having the V_H region of the murine B-Ly1 antibody, or variants thereof; and~~

~~b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~23. An isolated polynucleotide comprising~~

~~a. a sequence encoding a polypeptide having the V_L region of the murine B-Ly1 antibody, or variants thereof; and~~

~~b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~24.~~5. An expression vector comprising a polynucleotide encoding a heavy chain variable region of any one of claims 1 to 4 and a ~~an isolated~~ polynucleotide encoding a light chain variable region of any one of claims 1 or 4~~according to any one of claims 1-23~~.

~~25.~~6. The vector of claim ~~24~~5, ~~wherein said vector~~which is polycistronic.

~~26.~~7. An isolated host cell comprising the expression vector of claim ~~24~~5 or claim 6 or a polynucleotide encoding a heavy chain variable region of any one of claims 1 to 4 and a polynucleotide encoding a light chain variable region of any one of claims 1 or 4.

~~27. A host cell comprising an isolated polynucleotide according to any one of claims 1-23.~~

~~28. A polypeptide comprising a sequence derived from the murine B-Ly1 antibody and a sequence derived from a heterologous polypeptide.~~

8. The host cell of claim 7, wherein said host cell is engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosylaminyltransferase III activity.

9. The host cell of claim 8, wherein said polypeptide having β(1,4)-N-acetylglucosylaminyltransferase III activity is a fusion polypeptide further comprising the Golgi localization domain of a heterologous Golgi resident polypeptide.

10. The host cell of claim 9, wherein said Golgi localization domain is selected from the localization domain of mannosidase II, the localization domain of β(1,2)-N-acetylglucosaminyltransferase I, β(1,2)-N-acetylglucosaminyltransferase II, mannosidase I or α1-6 core fucosyltransferase.

11. A method for the production of a humanized Type-II anti-CD20 antibody of any one of claims 1 to 4 comprising culturing the host cell of any one of claims 7 to 10 under conditions that allow for the production of said antibody and recovering said antibody from said culture.

12. A humanized Type II anti-CD20 antibody, wherein the antibody is produced by the host cell of any one of claims 7 to 10.

13. The antibody of any one of claims 1 to 4 or 12, or produced by the method of claim 11, wherein said antibody comprises a glycoengineered Fc region.

14. The antibody of claim 13, wherein said antibody has an increase in the fraction of non-fucosylated oligosaccharides attached to said glycoengineered Fc region.

15. The antibody of claim 13, wherein said antibody has an increase in the fraction of bisected, non-fucosylated oligosaccharides attached to said glycoengineered Fc region.

16. The antibody of claim 13, wherein said antibody has significantly higher levels of binding to human FcgammaRIII receptors relative to the non-glycoengineered antibody.

17. The antibody of claim 13, wherein said antibody has significantly higher levels of ADCC activity relative to the non-glycoengineered antibody

~~29. An antigen-binding molecule comprising the polypeptide of claim 28.~~

~~30. An antigen-binding molecule according to claim 29, which binds human CD20.~~

~~31. An antigen-binding molecule according to claim 29, which is an antibody.~~

~~32. An antigen-binding molecule according to claim 31, which is a chimeric antibody.~~

~~33. An antigen-binding molecule according to claim 31, which is a humanized antibody.~~

~~34. An antigen-binding molecule according to claim 31, which is a primatized antibody.~~

~~35. A chimeric polypeptide comprising the sequence of SEQ ID NO:1 or a variant thereof.~~

~~36. A chimeric polypeptide comprising the sequence of SEQ ID NO:2 or a variant thereof.~~

~~37. A chimeric polypeptide comprising:~~

~~a. a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO: 17; and~~

~~b. a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO: 27; and~~

~~c. SEQ ID NO:28.~~

~~38. A chimeric polypeptide according to claim 37, further comprising a heavy chain variable region framework, wherein said framework comprises an alanine residue at position 71, according to Kabat numbering.~~

~~39. A chimeric polypeptide according to claim 37, further comprising a heavy chain variable region framework, wherein said framework comprises an arginine residue at position 94, according to Kabat numbering.~~

~~40. A chimeric polypeptide comprising SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO: 20.~~

~~41. An isolated polypeptide comprising SEQ ID NO:13 or a variant thereof.~~

~~42. An isolated polypeptide comprising SEQ ID NO:14 or a variant therof.~~

~~43. The isolated polypeptide according to any of claims 35-40, wherein said polypeptide is a fusion polypeptide.~~

~~44. An antigen binding molecule comprising the isolated polypeptide of claim 43.~~

~~45. The antigen binding molecule of claim 44, wherein said antigen binding molecule is an antibody.~~

~~46. The antibody of claim 45, wherein said antibody is a primatized antibody.~~

~~47. The antibody of claim 45, wherein said antibody is a humanized antibody.~~

~~48. The antigen binding molecule of claim 44, wherein said antigen binding molecule is an antibody fragment.~~

~~49. The antibody fragment of claim 48, wherein said antibody fragment is primatized.~~

~~50. The antigen binding molecule of claim 48, wherein said antibody fragment is humanized.~~

~~51. An antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to CD20, wherein said antigen binding molecule is chimeric.~~

~~52. The antigen binding molecule of claim 51, wherein said antigen binding molecule is an antibody.~~

~~53. The antigen binding molecule of claim 52, wherein said antibody is primatized.~~

~~54. The antigen binding molecule of claim 51, wherein said recombinant antibody is humanized.~~

~~55. The antigen binding molecule of claim 51, wherein said recombinant antibody comprises a human Fc region.~~

~~56. The antigen binding molecule of claim 55, wherein said human Fc region is a human IgG Fc region.~~

~~57. An antigen binding molecule of any of claims 29-34 or 44-56, said antigen binding molecule having an Fc region with modified oligosaccharides.~~

~~58. An antigen binding molecule according to claim 57, wherein said Fc region has been modified to have reduced fucose residues as compared to non-modified antigen binding molecule.~~

~~59. An antigen binding molecule according to claim 57, wherein said Fc region has an increased proportion of bisected oligosaccharides.~~

~~60. An antigen binding molecule according to claim 59, wherein said modified oligosaccharides are bisected complex.~~

~~61. An antigen binding molecule according to claim 57, wherein said modified oligosaccharides have an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said antigen binding molecule.~~

~~62. An antigen binding molecule according to claim 61, wherein said bisected, nonfucosylated oligosaccharides are hybrid.~~

~~63. An antigen binding molecule according to claim 61, wherein said bisected, nonfucosylated oligosaccharides are complex.~~

~~64. An antigen binding molecule according to claim 57, wherein at least 20% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~65. An antigen binding molecule according to claim 57, wherein at least 30% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~66. An antigen binding molecule according to claim 57, wherein at least 35% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~67. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~68. A method of producing an antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to human CD20, and wherein said antigen binding molecule is chimeric; said method comprising~~

~~a. culturing the host cell of claim 26 or claim 27 in a medium under conditions allowing the expression of said polynucleotide encoding said antigen binding molecule; and~~

~~b. recovering said antigen binding molecule from the resultant culture.~~

~~69. The method of claim 68, wherein said antigen binding molecule is an antibody.~~

~~70.~~18. A pharmaceutical composition comprising the antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11,~~the antigen binding molecule according to any of claims 29-34 or 46-67~~ and a pharmaceutically acceptable carrier.

~~71. The pharmaceutical composition of claim 70, wherein said composition further comprises a pharmaceutically acceptable carrier.~~

~~72. The pharmaceutical composition of claim 70, wherein said composition further comprises an adjuvant.~~

19. An antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11, for use in therapy.

20. Use of antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11, in the manufacture of a medicament for treating a B-cell disorder.

21. The antibody of claim 20, wherein said B-cell disorder is a B-cell lymphoma.

22. Use of the antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11, in the manufacture of a medicament to treat a disorder treatable by B-cell depletion.

23. An antibody of any one of claims 1 to 4 or 12 to 17, or produced by the method of claim 11, for use in therapy.

24. The use of claim 22, wherein said disorder is a haematological malignancy or an autoimmune disease.

25. The use of claim 24, wherein said haematological malignancy is B-cell lymphoma, non-Hodgkin's lymphoma, or B-cell chronic lymphocytic leukaemia.

26. The use of claim 24, wherein said autoimmune disease is rheumatoid arthritis or lupus.

~~73. A method of treating a disorder treatable by B-cell depletion comprising administering a therapeutically effective amount of pharmaceutical composition of any of claims 70-72 to a human subject in need thereof.~~

~~74. A host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide is an antigen binding molecule according to any of claims 44-67.~~

~~75. The host cell of claim 74, wherein said polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity is a fusion polypeptide.~~

~~76. The host cell of claim 74, wherein said antigen binding molecule is an antibody.~~

77. The host cell of claim 74, wherein said antigen binding molecule is an antibody fragment.

78. The host cell of claim 74, wherein said antigen binding molecule comprises a region equivalent to the Fc region of a human IgG.

79. The host cell of claim 74, wherein said antigen binding molecule produced by said host cell exhibits increased Fc receptor binding affinity as a result of said modification.

80. The host cell of claim 74, wherein said antigen binding molecule produced by said host cell exhibits increased effector function as a result of said modification.

81. A host cell according to claim 75, wherein said fusion polypeptide comprises the catalytic domain of β(1,4)-N-acetylglucosaminyltransferase III.

82. A host cell according to claim 75, wherein said fusion polypeptide further comprises the Golgi localization domain of a heterologous Golgi resident polypeptide.

83. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of mannosidase II.

84. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of β(1,2) N-acetylglucosaminyltransferase I.

85. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of β(1,2) N-acetylglucosaminyltransferase II.

86. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of mannosidase I.

~~87. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of α1-6 core fucosyltransferase.~~

~~88. A host cell according to claim 80, wherein said increased effector function is increased Fc-mediated cellular cytotoxicity.~~

~~89. A host cell according to claim 80, wherein said increased effector function is increased binding to NK cells.~~

~~90. A host cell according to claim 80, wherein said increased effector function is increased binding to macrophages.~~

~~91. A host cell according to claim 80, wherein said increased effector function is increased binding to polymorphonuclear cells.~~

~~92. A host cell according to claim 80, wherein said increased effector function is increased binding to monocytes.~~

~~93. A host cell according to claim 80, wherein said increased effector function is increased direct signaling inducing apoptosis.~~

~~94. A host cell according to claim 80, wherein said increased effector function is increased dendritic cell maturation.~~

~~95. A host cell according to claim 80, wherein said increased effector function is increased T cell priming.~~

~~96. A host cell according to claim 79, wherein said Fc receptor is Fcγ activating receptor.~~

97. A host cell according to claim 79, wherein said Fc receptor is FcγRIIIA receptor.

98. A host cell according to claim 74, wherein said host cell is a CHO cell, a BHK cell, a NSO cell, a SP2/0 cell, a YO myeloma cell, a P3X63 mouse myeloma cell, a PER cell, a PER.C6 cell or a hybridoma cell.

99. The host cell of claim 74, further comprising at least one transfected polynucleotide encoding a polypeptide according to any of claims 28 and 35-41, and wherein said nucleic acid comprises a sequence encoding a region equivalent to the Fc region of a human immunoglobulin.

100. The host cell of claim 74, wherein said at least one nucleic acid encoding a polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity is operably linked to a constitutive promoter element.

101. The host cell of claim 100, wherein said polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity is a fusion polypeptide.

102. A method for producing an antigen binding molecule having modified oligosaccharides in a host cell, said method comprising:

a. culturing a host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity under conditions which permit the production of said antigen binding molecule, and which permit the modification of the oligosaccharides present on the Fc region of said antigen binding molecule; and

b. isolating said antigen binding molecule wherein said antigen binding molecule is capable of competing with the murine B-Ly1 antibody for binding to CD20 and wherein said antigen binding molecule or fragment thereof is chimeric.

103. A method according to claim 102, wherein said modified oligosaccharides have reduced fucosylation as compared to non-modified oligosaccharides.

~~104. A method according to claim 102, wherein said modified oligosaccharides are hybrid.~~

~~105. A method according to claim 102, wherein said modified oligosaccharides are complex.~~

~~106. A method according to claim 102, wherein said recombinant antibody or fragment thereof produced by said host cell has an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said polypeptide.~~

~~107. A method according to claim 106, wherein said bisected, nonfucosylated oligosaccharides are hybrid.~~

~~108. A method according to claim 106, wherein said bisected, nonfucosylated oligosaccharides are complex.~~

~~109. A method according to claim 102, wherein at least 20% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~110. A method according to claim 102, wherein at least 30% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~111. A method according to claim 102, wherein at least 35% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~112. An antigen binding molecule engineered to have increased effector function produced by the method according to any one of claims 102-111.~~

~~113. The antigen binding molecule of claim 112, wherein said antigen binding molecule is an antibody~~

~~114. An antibody engineered to have increased Fc receptor binding affinity produced by the method of any one of claims 102-111.~~

~~115. The antigen binding molecule of claim 114, wherein said antigen binding molecule is an antibody.~~

~~116. An antigen binding molecule according to claim 112, wherein said increased effector function is increased Fc-mediated cellular cytotoxicity.~~

~~117. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to NK cells.~~

~~118. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to macrophages.~~

~~119. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to monocytes.~~

~~120. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to polymorphonuclear cells.~~

~~121. An antigen binding molecule according to claim 112, wherein said increased effector function is direct signaling inducing apoptosis.~~

~~122. An antigen binding molecule according to claim 112, wherein said increased effector function is increased dendritic cell maturation.~~

~~123. An antigen binding molecule according to claim 112, wherein said increased effector function is increased T cell priming.~~

~~124. An antigen binding molecule according to claim 114, wherein said Fc receptor is Fc activating receptor.~~

~~125. An antigen binding molecule according to claim 114, wherein said Fc receptor is FcγRIIIa receptor.~~

~~126. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is an antibody fragment containing the Fc region and engineered to have increased effector function.~~

~~127. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:1 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.~~

~~128. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.~~

~~129. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:3 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.~~

~~130. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:76 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.~~

~~131. A pharmaceutical composition comprising the antigen binding molecule of any of claims 112 to 130 and a pharmaceutically acceptable carrier.~~

~~132. A pharmaceutical composition comprising the antibody fragment of claim 126 and a pharmaceutically acceptable carrier.~~

~~133. A pharmaceutical composition comprising the fusion protein of any of claims 127 to 130 and a pharmaceutically acceptable carrier.~~

~~134. A method of treating a disease treatable by B-cell depletion comprising administering a therapeutically effective amount of the antigen binding according to any of claims 112 to 130 to a human subject in need thereof.~~

~~135. An isolated polynucleotide according to claim 4 or 5 further comprising a sequence encoding a human antibody light or heavy chain constant region.~~

~~136. An isolated polynucleotide comprising a sequence with at least 80% identity to SEQ ID NO:24, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~137. A host cell coexpressing an isolated polynucleotide according to claim 136 and a polynucleotide comprising a sequence encoding the variable region of an antibody light chain.~~

~~138. An antigen binding molecule according to claim 57, wherein at least 50% of the oligosaccharides in the Fc region are bisected.~~

~~139. An antigen binding molecule according to claim 57, wherein at least 60% of the oligosaccharides in the Fc region are bisected.~~

~~140. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosaccharides in the Fc region are bisected.~~

~~141. An antigen binding molecule according to claim 57, wherein at least 80% of the oligosaccharides in the Fc region are bisected.~~

~~142. An antigen binding molecule according to claim 57, wherein at least 90% of the oligosaccharides in the Fc region are bisected.~~

~~143. An antigen binding molecule according to claim 57, wherein at least 50% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~144. An antigen binding molecule according to claim 57, wherein at least 60% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~145. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~146. An antigen binding molecule according to claim 57, wherein at least 75% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~147. A method according to claim 73, wherein said disorder is a B cell lymphoma.~~

~~148. An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID~~

~~No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.~~

~~149. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:31.~~

~~150. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:55.~~

~~151. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:59.~~

~~152. An isolated polynucleotide comprising SEQ ID No:75.~~

~~153. An isolated polynucleotide according to claim 148 or 149, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~154. An isolated polynucleotide comprising~~

~~a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and~~

~~b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76~~

~~155. An isolated polynucleotide comprising a sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and~~

~~SEQ ID No:71, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~156. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:75, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~157. An isolated polynucleotide comprising a sequence having at least 85% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.~~

~~158. An isolated polynucleotide comprising a sequence having at least 85% identity to SEQ ID No: 75.~~

~~159. An isolated polynucleotide comprising a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.~~

~~160. An isolated polynucleotide comprising a sequence having at least 90% identity to SEQ ID No: 75.~~

~~161. An isolated polynucleotide comprising a sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ~~

~~ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.~~

~~162. An isolated polynucleotide comprising a sequence having at least 95% identity to SEQ ID No: 75.~~

~~163. An isolated polynucleotide comprising a sequence having at least 99% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.~~

~~164. An isolated polynucleotide comprising a sequence having at least 99% identity to SEQ ID No: 75.~~

~~165. An isolated polynucleotide comprising~~

~~a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72; and~~

~~b) a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~166. An isolated polynucleotide comprising~~

~~a) a sequence encoding a polypeptide having the sequence of SEQ ID No:76; and~~

~~b) a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.~~

~~167. An isolated polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72.~~

~~168. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No:76.~~

~~169. An isolated polynucleotide comprising a sequence that encodes a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72.~~

~~170. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:76.~~

~~171. An expression vector comprising an isolated polynucleotide according to any one of claims 148-170.~~

~~172. The vector of claim 171, wherein said vector is polycistronic.~~

~~173. A host cell comprising the expression vector of claim 171.~~

~~174. A host cell comprising an isolated polynucleotide according to any one of claims 148-170.~~

~~175. A humanized polypeptide comprising a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, or a variant thereof.~~

~~176. A humanized polypeptide comprising the sequence of SEQ ID NO:76, or a variant thereof.~~

~~177. An isolated polypeptide comprising a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, or a variant thereof.~~

~~178. An isolated polypeptide comprising SEQ ID NO:76, or a variant thereof.~~

~~179. The isolated polypeptide according to any of claims 177-178, wherein said polypeptide is a fusion polypeptide.~~

~~180. An antigen binding molecule comprising the isolated polypeptide of claim 179.~~

~~181. The antigen binding molecule of claim 180, wherein said antigen binding molecule is an antibody.~~

~~182. The antibody of claim 181, wherein said antibody is a humanized antibody.~~

~~183. The antigen binding molecule of claim 180, wherein said antigen binding molecule is an antibody fragment.~~

~~184. The antigen binding molecule of claim 183, wherein said antibody fragment is humanized.~~

~~185. The antigen binding molecule of claim 180, wherein said antigen binding molecule is a recombinant antibody.~~

~~186. The antigen binding molecule of claim 185, wherein said recombinant antibody is humanized.~~

~~187. The antigen binding molecule of claim 180, wherein said recombinant antibody comprises a human Fc region.~~

~~188. The antigen binding molecule of claim 187, wherein said human Fc region is a human IgG Fc region.~~

~~189. An antigen binding molecule of any of claims 180-188, said antigen binding molecule having an Fc region with modified oligosaccharides.~~

~~190. An antigen binding molecule according to claim 189, wherein said Fc region has been modified to have reduced fucose residues as compared to non-modified antigen binding molecule.~~

~~191. An antigen binding molecule according to claim 189, wherein said Fc region has an increased proportion of bisected oligosaccharides.~~

~~192. An antigen binding molecule according to claim 189, wherein said modified oligosaccharides are bisected complex.~~

~~193. An antigen binding molecule according to claim 189, wherein said modified oligosaccharides have an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said antigen binding molecule.~~

~~194. An antigen binding molecule according to claim 193, wherein said bisected, nonfucosylated oligosaccharides are hybrid.~~

~~195. An antigen binding molecule according to claim 193, wherein said bisected, nonfucosylated oligosaccharides are complex.~~

~~196. An antigen binding molecule according to claim 189, wherein at least 20% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~197. An antigen binding molecule according to claim 189, wherein at least 30% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~198. An antigen binding molecule according to claim 189, wherein at least 35% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~199. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.~~

~~200. A method of producing an antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to human CD20, and wherein said antigen binding molecule is chimeric; said method comprising~~

~~a) culturing the host cell of claim 173 or claim 174 in a medium under conditions allowing the expression of said polynucleotide encoding said antigen binding molecule; and~~

~~b) recovering said antigen binding molecule.~~

~~201. The method of claim 200, wherein said antigen binding molecule is an antibody.~~

~~202. The method of claim 200, wherein said chimeric antigen binding molecule is humanized.~~

~~203. A pharmaceutical composition comprising the antigen binding molecule according to any of claims 189-199 and a pharmaceutically acceptable carrier.~~

~~204. The pharmaceutical composition of claim 203, wherein said composition further comprises a pharmaceutically acceptable carrier.~~

~~205. The pharmaceutical composition of claim 203, wherein said composition further comprises an adjuvant.~~

~~206. A method of treating a disorder treatable by B-cell depletion comprising administering a therapeutically effective amount of pharmaceutical composition of any of claims 203-205 to a human subject in need thereof.~~

~~207. A host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide is an antigen binding molecule according to any of claims 180-197.~~

~~208. The host cell of claim 207, wherein said polypeptide having β(1,4) N-acetylglucosaminyltransferase III activity is a fusion polypeptide.~~

~~209. The host cell of claim 207, wherein said antigen binding molecule is an antibody.~~

~~210. The host cell of claim 207, wherein said antigen binding molecule is an antibody fragment.~~

~~211. The host cell of claim 207, wherein said antigen binding molecule comprises a region equivalent to the Fc region of a human IgG.~~

~~212. The host cell of claim 207, wherein said antigen binding molecule produced by said host cell exhibits increased Fc receptor binding affinity as a result of said modification.~~

~~213. The host cell of claim 207, wherein said antigen binding molecule produced by said host cell exhibits increased effector function as a result of said modification.~~

~~214. A host cell according to claim 208, wherein said fusion polypeptide comprises the catalytic domain of β(1,4) N-acetylglucosaminyltransferase III.~~

~~215. A host cell according to claim 208, wherein said fusion polypeptide further comprises the Golgi localization domain of a heterologous Golgi resident polypeptide.~~

~~216. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of mannosidase II.~~

~~217. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of β(1,2) N acetylglucosaminyltransferase I.~~

~~218. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of β(1,2) N acetylglucosaminyltransferase II.~~

~~219. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of mannosidase I.~~

~~220. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of α1 6 core fucosyltransferase.~~

~~221. A host cell according to claim 213, wherein said increased effector function is increased Fc mediated cellular cytotoxicity.~~

~~222. A host cell according to claim 213, wherein said increased effector function is increased binding to NK cells.~~

~~223. A host cell according to claim 213, wherein said increased effector function is increased binding to macrophages.~~

~~224. A host cell according to claim 213, wherein said increased effector function is increased binding to polymorphonuclear cells.~~

~~225. A host cell according to claim 213, wherein said increased effector function is increased binding to monocytes.~~

~~226. A host cell according to claim 213, wherein said increased effector function is increased direct signaling inducing apoptosis.~~

~~227. A host cell according to claim 213, wherein said increased effector function is increased dendritic cell maturation.~~

~~228. A host cell according to claim 213, wherein said increased effector function is increased T cell priming.~~

~~229. A host cell according to claim 212, wherein said Fc receptor is Fcγ activating receptor.~~

~~230. A host cell according to claim 212, wherein said Fc receptor is FcγRIIIA receptor.~~

~~231. A host cell according to claim 207, wherein said host cell is a CHO cell, a BHK cell, a NSO cell, a SP2/0 cell, a YO myeloma cell, a P3X63 mouse myeloma cell, a PER cell, a PER.C6 cell or a hybridoma cell.~~

~~232. The host cell of claim 207, further comprising at least one transfected polynucleotide encoding a polypeptide according to any of claims 28 and 35-41, and wherein said nucleic acid comprises a sequence encoding a region equivalent to the Fc region of a human immunoglobulin.~~

~~233. The host cell of claim 207, wherein said at least one nucleic acid encoding a polypeptide having β(1,4) N acetylglucosaminyltransferase III activity is operably linked to a constitutive promoter element.~~

~~234. The host cell of claim 233, wherein said polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is a fusion polypeptide.~~

~~235. An antigen binding molecule according to claim 189, wherein at least 50% of the oligosaccharides in the Fc region are bisected.~~

~~236. An antigen binding molecule according to claim 189, wherein at least 60% of the oligosaccharides in the Fc region are bisected.~~

~~237. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region are bisected.~~

~~238. An antigen binding molecule according to claim 189, wherein at least 80% of the oligosaccharides in the Fc region are bisected.~~

~~239. An antigen binding molecule according to claim 189, wherein at least 90% of the oligosaccharides in the Fc region are bisected.~~

~~240. An antigen binding molecule according to claim 189, wherein at least 50% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~241. An antigen binding molecule according to claim 189, wherein at least 60% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~242. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~243. An antigen binding molecule according to claim 189, wherein at least 75% of the oligosaccharides in the Fc region are nonfucosylated.~~

~~244. A method according to claim 206, wherein said disorder is a B cell lymphoma.~~

~~245. An isolated polynucleotide comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at least the specificity determining residues for said complementarity determining region, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~246. An isolated polynucleotide according to claim 245, wherein said complementarity determining region is selected from the group consisting of : [LIST ALL B-Ly1 CDR SEQUENCES].~~

~~247. An isolated polynucleotide according to claim 245, wherein said isolated polynucleotide encodes an antigen binding molecule.~~

~~248. An isolated polynucleotide comprising at least three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity determining residues for each of said three complementarity determining regions, wherein said isolated polynucleotide encodes a fusion polypeptide.~~

~~249. An isolated polynucleotide according to claim 248, wherein said complementarity determining regions comprise at least one sequence selected from the group consisting of : SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; and at least one sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23; and SEQ ID NO:24, or variants or truncated forms of said sequences that contain at least the specificity determining residues for each of said complementarity determining regions.~~

~~250. An isolated polypeptide encoded by the isolated polynucleotides of any of claims 245-249.~~

~~251. An antigen binding molecule comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at lest the specificity determining residues for said complementarity determining region, and further comprising a sequence derived from a heterologous polypeptide.~~

~~252. An antigen binding molecule according to claim 251, wherein said antigen binding molecule comprises at least three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity determining residues for each of said complementarity determining regions.~~

~~253. An antigen binding molecule according to claim 252, wherein said antigen binding molecule comprises the variable region of an antibody light or heavy chain.~~

~~254. An antigen binding molecule according to claim 252, wherein said antigen binding molecule is a chimeric or humanized, antibody.~~

~~255. An engineered Type II anti-CD20 antibody having increased ADCC as a result of said engineering without substantial loss of ability to induce apoptosis of target cells.~~

~~256. An engineered Type II anti-CD20 antibody according to claim 255, wherein said antibody has been engineered to have an altered pattern of glycosylation in the Fc region.~~

~~257. An engineered Type II anti-CD20 antibody according to claim 256, wherein said altered glycosylation is an increase in the amount of bisected complex oligosaccharides.~~

~~258. An engineered Type II anti-CD20 antibody according to claim 256, wherein said altered glycosylation is a decrease in the amount of fucose residues.~~

~~259. An engineered Type II anti-CD20 antibody according to claim 255, wherein said antibody has been engineered to have an altered amino acid sequence in the Fc region.~~